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I. GENERAL INTRODUCTION 
Schizophrenia is a major psychiatric disorder with a high prevalence of about 1%, 
primarily characterized by positive symptoms, negative symptoms and cognitive 
impairment. All current medication for schizophrenia, called “antipsychotics”, have some 
actions on dopamine D2 receptor. Conventional typical antipsychotics have potent D2 
antagonism effect and are remarkably effective for positive symptoms, but have limited 
effect on negative symptoms and cognitive impairment. Furthermore, extrapyramidal 
symptoms (EPS) and hyperprolactinemia have been reported as adverse reactions. New 
generation atypical antipsychotics which have wide range of actions on multiple receptors 
such as serotonin 5-HT2 receptor in addition to D2 receptor shows better efficacy on 
negative symptoms and cognitive impairment and improved side effect profile, but the 
total effect is not satisfactory, and there are new issues such as metabolic side effects. 
There remain the unmet needs for more effective and safer treatment for schizophrenia. 
Phosphodiesterase 10A (PDE10A), a dual hydrolase of cAMP and cGMP, is highly 
expressed in medium spiny neurons in the striatum. Striatum mainly includes Gs-coupled 
D1 receptor-expressing neurons and Gi-coupled D2-expressing neurons that form direct 
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Figure 1. Schematic representation of the corticostriatothalamic pathway. 
AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; D1R, dopamine D1 receptor; 
D2R, dopamine D2 receptor; DA, dopamine; GABA, γ-aminobutyric acid ; Glu, Glutamate; Gpe, external 
segment of globus pallidus; Gpi, internal segment of globus pallidus; NMDAR, N-methyl-D-aspartate 
receptor; SNc, substantia nigra pars compacta; SNr, Substantia nigra pars reticulata; STN, Subthalamic 
nucleus 
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pathway and indirect pathway, respectively (Figure 1). In the striatum, dopaminergic 
input from the midbrain and glutamatergic input from the cortex are integrated, and the 
balance of outputs from direct pathway and indirect pathway controls various functions 
such as motor function, cognitive function, motivation and learning. Inhibition of 
PDE10A could modulate the balance by inhibition of cAMP degradation, amplifying the 
intracellular signals and outputs of both direct pathway and indirect pathway. Therefore, 
PDE10A inhibitors are expected to be a new therapeutic agent for schizophrenia. 
In the last decade, several PDE10A inhibitors have been developed as the treatment 
of schizophrenia. Although promising data of preclinical studies, two leading compounds 
MP-10 and TAK-063 did not success the clinical trials for schizophrenia. In this study, 
another two PDE10A inhibitors, T-251 and MT-3014 (Figure 2) were investigated in 
rodent models of schizophrenia, and the potential of PDE10A inhibitors for the treatment 
of schizophrenia and strategies to success the clinical trials were discussed. 
A B 
       
In chapter 1, we investigated the effects of T-251 on schizophrenia models of rodents. 
In chapter 2, we investigated the effects of MT-3014 on same models, and additionally 
evaluated the brain occupancy of MT-3014 using a specific PDE10A ligand in rats. Based 
on these studies, we discussed the potential of PDE10A inhibitor for the treatment of 
schizophrenia and propose the future plan to succeed the clinical trials. 
Figure 2. Chemical structures of (A) T-251 and (B) MT-3014 
(A) T-251: 2-[(E)-2-(7-fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-
pyran-4-yl)pyrimidin-4-amine hydrochloride; (B) MT-3014: 1-({2-(7-Fluoro-3-methylquinoxalin-2-yl)-
5-[(3R)-3-fluoropyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)-2-methylpropan-2-ol 
hydrochloride 
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II. CHAPTER 1 
ANTIPSYCHOTIC-LIKE EFFECTS OF A NOVEL 
PHOSPHODIESTERASE 10A INHIBITOR T-251 IN RODENTS 
 
1 Abstract 
Phosphodiesterase 10A (PDE10A) is a dual-substrate PDE that hydrolyzes both 
cAMP and cGMP. PDE10A is selectively expressed in medium spiny neurons in the 
striatum, suggesting the potential of PDE10A inhibitors in the treatment of schizophrenia. 
This study presents the pharmacological profile of a novel PDE10A inhibitor, 2-[(E)-2-
(7-fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-
yl)pyrimidin-4-amine hydrochloride (T-251) in rodent models of schizophrenia. T‐251 
showed a potent inhibitory activity against human PDE10A (IC50 = 0.050 nmol/L) and 
showed high selectivity over other PDE families which have over 10,000-fold IC50 values. 
Oral administration of T-251 (0.1–1.0 mg/kg) increased cAMP and cGMP in the striatum 
in a dose-dependent manner. Oral administration of T-251 attenuated MK-801 induced 
hyperactivity (ED50 = 0.68 mg/kg) and suppressed conditioned avoidance response 
(ID50 = 0.87 mg/kg) in rats in a dose dependent manner. Furthermore, T-251 significantly 
attenuated MK-801 induced prepulse inhibition deficits and cognitive deficits in rats. 
Unlike haloperidol and olanzapine, T-251 (1.0–30 mg/kg) did not cause catalepsy in rats. 
Moreover, T-251 (0.6 and 6.0 mg/kg) did not increase plasma levels of prolactin at 1 hour 
after administration, whereas haloperidol and olanzapine significantly increased them. 
The antipsychotic-like effects and cognitive enhancement of T-251 without catalepsy or 
plasma prolactin elevation observed in rats suggests that T-251 would be a novel 
antipsychotic with an improved side-effect profile. 
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2 Introduction 
Schizophrenia is a major psychiatric disorder characterized primarily by positive 
symptoms, negative symptoms and cognitive impairment. The current antipsychotics are 
full antagonists and partial agonists of dopamine D2 receptors; however, the efficacy of 
current antipsychotics is still not satisfactory (Citrome, 2014; Corponi et al., 2019; Forray 
and Buller, 2017). Although atypical antipsychotics could reduce the risk of 
extrapyramidal symptoms (EPS) of typical antipsychotics, efficacy is considerably 
limited for negative symptoms and cognitive impairment (Forray and Buller, 2017; 
Serretti et al., 2004). In addition, atypical antipsychotics are also associated with 
hyperprolactinemia, osteoporosis possibly induced by hyperprolactinemia, and serious 
metabolic side effects, including hyperglycemia, weight gain, and diabetes (De Hert et 
al., 2016; Krebs et al., 2006; Serretti et al., 2004; Tschoner et al., 2007). Recently, long-
acting injectable antipsychotics are reported to be more effective for cognitive 
impairment (Correll et al., 2016; Guillena and Garcia de Diego, 2019), but it is still 
necessary to develop new drugs that are more convenient and effective in the treatment 
of negative symptoms and cognitive impairment in schizophrenia. 
Phosphodiesterase 10A (PDE10A), a dual hydrolase of cAMP and cGMP, is highly 
expressed in medium spiny neurons (MSNs) in the striatum (Fujishige et al., 1999a; 
Fujishige et al., 1999b; Seeger et al., 2003; Soderling et al., 1999; Xie et al., 2006). One 
of the substrates of PDE10A, cAMP, is the major second messenger downstream of G 
protein-coupled receptors, including Gs-coupled dopamine D1 receptor and Gi-coupled 
D2 receptor (Beaulieu et al., 2015). Inhibition of PDE10A induces elevation of cAMP, 
and subsequently activates cAMP/ protein kinase A (PKA) signaling in both D1- and D2- 
type neurons with an agonist-like effect against D1 receptor and an antagonist-like effect 
against D2 receptor. Activation of both D1- type neurons and D2-type neurons are 
expected to reduce the risk of EPS retaining the antipsychotic effects by balancing the 
striatal total output. Furthermore, activation of MSNs in the striatum, where cortical 
glutamatergic and midbrain dopaminergic inputs are integrated, could recover a 
hypoglutamatergic state-induced weakened striatal output which seems to be related with 
cognitive impairment and negative symptoms (Kehler and Nielsen, 2011; Snyder and 
Vanover, 2014). Thus, PDE10A inhibition has attracted attention as a new therapeutic 
approach which satisfies present unmet needs of schizophrenia.  
In the last decade, several PDE10A inhibitors [i.e., MP-10 (PF-02545920), TAK-
063 (Balipodect), PDM-042] have been discovered as candidates of antipsychotics 
(Arakawa et al., 2016; Geerts et al., 2017; Grauer et al., 2009; Kehler, 2013; Kehler and 
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Nielsen, 2011; Snyder and Vanover, 2017; Suzuki et al., 2015; Zagorska et al., 2018). A 
number of preclinical studies have demonstrated that the inhibition of PDE10A is 
effective not only for positive symptoms but also for negative symptoms and cognitive 
deficits in rodents (Arakawa et al., 2017; Grauer et al., 2009; Langen et al., 2012; Shiraishi 
et al., 2016). Importantly, PDE10A inhibitors have much less side effects than the current 
antipsychotics in rodents (Arakawa et al., 2016; Grauer et al., 2009; Suzuki et al., 2015). 
Recently, we reported the discovery of a novel PDE10A inhibitor, 2-[(E)-2-(7-
fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-
yl)pyrimidin-4-amine hydrochloride (compound 32, T-251) (Kadoh et al., 2018). In the 
present study, we report the antipsychotic-like effects and side effect profiles of T-251 in 
rodents.  
 
3 Materials and Methods 
3.1 Animals  
Male C57/BL 6Cr mice (aged 7 weeks, body weight 20.3–25.8 g, Japan SLC, Inc., 
Hamamatsu, Japan) were used for the brain cAMP/cGMP study. Male Wistar rats (Japan 
SLC, Inc., Hamamatsu, Japan) were used for the locomotor activity study (aged 7–
8 weeks, body weight 144–249 g), prepulse inhibition (PPI) test (aged 8 weeks, body 
weight 177–219 g) and prolactin measurement (aged 6 weeks, body weight 120–140 g). 
Male Wistar rats (Japan Charles River Inc., Yokohama, Japan) were used for the 
conditioned avoidance response (CAR) test (aged 8–12 weeks, body weight 260–437 g) 
and the catalepsy test (aged 7–8 weeks, body weight 147–195 g). Male Listar hooded rats 
(aged 7–8 weeks, body weight 208–286 g, Kyudo Co., Ltd., Saga, Japan) were used for 
the novel object recognition test (NORT).  
All animals were housed under environmentally controlled conditions; 12-h 
light/dark cycle (lights on at 7:00 AM), setting temperature (permissive range): 23 (20–
26)°C, setting humidity (permissive range): 55 (30–70)% with access to food and water 
ad libitum. All in vivo experimental procedures were approved by the Institutional Animal 
Care and Use Committee of Research Laboratories, Mitsubishi Tanabe Pharma 
Corporation. 
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3.2 Test compounds 
T-251 and its 2 HCl salt (used in the catalepsy test) were synthesized at Mitsubishi 
Tanabe Pharma Corporation (Yokohama, Japan). T-251 was dissolved in dimethyl 
sulfoxide (DMSO) for the in vitro PDE assay or suspended in 0.5% 
(hydroxypropyl)methyl cellulose (HPMC)–0.1% Tween 80 (vehicle) for in vivo studies. 
As reference drugs, haloperidol was purchased from Sigma-Aldrich, Inc. (St. Louise, MO, 
USA), olanzapine and clozapine were synthesized at Mitsubishi Tanabe Pharma 
Corporation (Yokohama, Japan). All reference drugs were suspended in the same vehicle. 
Briefly, effects of T-251 were evaluated at 1 hour after oral administration in in vivo 
studies in consideration of convenience for clinical use. All reference drugs were 
evaluated at the same time point of T-251. (+)-MK-801 hydrogen maleate (MK-801: 
Sigma-Aldrich, Inc., St. Louise, MO, USA) was dissolved in saline. 
3.3 In vitro PDE assay 
PDE1, PDE3, PDE4, PDE5 and PDE6 were isolated by chromatography of rat 
ventricle, dog heart, dog lung, dog lung, bovine retina, respectively, according to the 
method modified from a previous report (Kotera et al., 2000). Human recombinant 
PDE2A, PDE7B, PDE8A, PDE9A, PDE10A and PDE11A were obtained from COS-7 
cells transfected with expression plasmids coded for each PDE subtype according to a 
method modified from previous reports (Gamanuma et al., 2003; Kotera et al., 1999; 
Sasaki et al., 2000; Yuasa et al., 2000). 
The PDE assay was performed by the radio-labeled nucleotide method (Thompson 
et al., 1979). Briefly, T-251, enzymes, substrates (approximate 40 nmol/L [5’,8-3H]cAMP 
or 163 nmol/L [8-3H]cGMP: GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and 0.2 
mg/mL snake venom were mixed in assay buffer (50 mmol/L Tris-HCl, pH 8.0, 12.5 
mmol/L MgCl2, 10 mmol/L 2-mercaptoethanol and 0.825 mg/mL bovine serum albumin) 
and incubated at room temperature for 90 minutes. The reaction was stopped by adding 
an equivalent volume of methanol. Resultant solutions were applied to a Dowex (1 × 8 
200–400) resin filter and then washed with methanol. The radioactivity of eluates was 
measured with a scintillation counter (TopCount NXT™: Packard Instrument Company, 
Inc., Meriden, CT, USA). The IC50 values were calculated by non-linear regression using 
logarithmic concentrations and % inhibition. 
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3.4 Measurement of striatal cAMP and cGMP level 
One hour after oral administration of T-251 (0.1, 0.3 or 1.0 mg/kg), mice were 
sacrificed by focused microwave irradiation to the brain. The striatum was isolated and 
homogenized in 0.5% Triton-X-100/phosphate buffered salts (PBS) and centrifuged at 
21,880 g at 4°C for 5 minutes. The concentrations of cAMP and cGMP in supernatants 
were measured using enzyme immunoassay (EIA) kits (Cat. No. RPN225 and RPN 226, 
GE Healthcare UK Limited, Buckinghamshire, UK).  
3.5 Locomotor activity 
Locomotor activity of rats were measured in Plexiglas boxes (45 × 45 × 25 cm) set 
in the SCANET system (MV-20plus®, MELQUEST Ltd., Toyama, Japan), equipped with 
infrared photocells on the X and Y-axes. T-251 (0.09, 0.3, 1.0 or 3.0 mg/kg) or vehicle 
was orally administered to rats 1 hour prior to measurements. For measurement of 
MK-801 induced hyperactivity, MK-801 (0.075 mg/kg) was subcutaneously injected just 
before the measurement. Rats were placed individually in the apparatus for 20 minutes 
for spontaneous activity tests and for 40 minutes for MK-801 induced hyperactivity. Total 
counts were measured, and ED50 values and their 95% confidence intervals (CI) were 
estimated by non-liner regression analysis.  
3.6 CAR test 
Conditioned avoidance behavior was assessed using automated shuttle-boxes (56 × 
21 × 25 cm, MSB-001, MELQUEST Ltd., Toyama, Japan) each placed in a sound-
attenuated chamber. The boxes were subdivided into two compartments by a partition 
with one opening. The position of rats and their movement from one compartment to the 
other were detected by photocells sensitive to infrared light on each side of the dividing 
wall. 
Rats were trained and tested in the automated shuttle-boxes. A session consisted of 
20 trials with 10 second inter-trial intervals. Each trial consisted of a 5 second tone 
(conditioned stimulus, CS) followed by a 10 second tone plus mild electric stimulus 
(0.8 mA, unconditioned stimulus, UCS) being applied to the grid floor. If the rat moved 
from one compartment to the other, the stimulus was immediately terminated. The 
following behavioral variables were recorded: avoidance (response to CS within 
5 seconds), escape failures (failure to respond to UCS). Only rats that showed a high level 
of avoidance response (at least 80%) on two or more consecutive days were used for 
evaluation of T-251. On the test day, rats were orally administered with T-251 (0.3, 1.0 
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or 3.0 mg/kg) or vehicle and tested 1, 3, 5, 7 and 24 hours later as described above. 
Avoidance response (%) and escape failure (%) at each time point was calculated. The 
ID50 values and its 95% CI for avoidance response at each time point were estimated by 
non-liner regression analysis. 
3.7 PPI test 
PPI tests were conducted using four SR-LAB® acoustic startle chambers (San Diego 
Instruments, San Diego, CA, USA), each consisting of a clear, nonrestrictive Plexiglas 
cylinder mounted on a platform and housed in ventilated, sound-attenuating external 
chambers. Rats placed inside the cylinders are stimulated with acoustic stimuli, triggering 
the whole-body startle response, which is detected by transducing movement into analog 
signals by a piezoelectric unit attached to the platform. A loudspeaker inside each 
chamber provided a continuous background noise of 70 dB. The session consists of five 
different trials; (1) PULSE ALONE trial (40 milliseconds, 120 dB), (2–4) PREPULSE 
trial (20 millisecond prepulses at 80, 85 or 90 dB and 40 milliseconds PULSE 
100 milliseconds after prepulse) and (5) NOSTIM trial (only the background noise) 
conducted in a pseudorandom order with an interval of 12–18 seconds. Each trial was 
conducted 12 times. The startle responses were averaged excluding the first time of each 
trial. PPI was calculated using the following formula: PPI (%) = 100-[{(PREPULSE-
NOSTIM) / (PULSE ALONE-NOSTIM)} *100]. On the day before the test, all rats 
underwent the baseline session. Rats that showed 10–299 responses in the PULSE 
ALONE trial and > 40% PPI (the average of PPI at 80, 85 and 90 dB) were used for the 
test session. In the test session, T-251 (1.0, 3.0 or 10 mg/kg) or vehicle were orally 
administered 1 hour before the start of the test. MK-801 (0.075 mg/kg) was 
subcutaneously injected 25 minutes before the start of the test. 
3.8 NORT 
The experiments were carried out in a test box (45.5 × 25 × 35 cm) set in the 
SCANET system (MV-10AQ®, MATYS Co., Tokyo, Japan), equipped with infrared 
photocells on the X and Y-axes. Two objects; a blue plastic cube (7 × 6 × 6 cm) and a 
white porcelain pyramid (6 × 6 × 6.5 cm) were positioned in two adjacent corners in-
touch of the walls of the test box. 
Rats were habituated to the test box for 5 minutes on the day before the test day. On 
the test day, T-251 (0.2 or 0.6 mg/kg), clozapine (3.0 mg/kg) or vehicle were orally 
administered 1 hour prior to intraperitoneal injection of MK-801 (0.05 mg/kg). The 
training session was conducted 10 minutes after MK-801 injection where rats were 
9 
 
exposed to two identical objects for 5 minutes. The test session was conducted 2 hours 
after the training session where rats were exposed to two objects for 5 minutes with one 
object replaced by a novel one. Object exploration was defined as the rats sniffing, licking, 
touching or biting. Exploration preference was calculated using the following formula: 
Exploration preference (%) = (time spent exploring the novel object) / (the total 
exploration time of the two objects) × 100. 
3.9 Catalepsy 
Rats were orally administered with T-251 or vehicle and tested 1, 3, 5 and 7 hours 
later for catalepsy by the bar test. Forepaws of the rats were placed on a 7 cm-high bar 
and recorded for how long they retained the same position. Rats were removed from the 
bar if their latency on the bar exceeded 60 seconds (i.e. cut-off time = 60 sec). The 
effective dose of 10 seconds (ED10s value) and its 95% CI for each compound was 
determined from the sum of total catalepsy time from 4 trials, to assess potency of the test 
compounds to induce catalepsy. ED10s were estimated by linear regression analysis. 
3.10 Plasma prolactin level 
Rats were sacrificed by decapitation under non-anesthesia at 1 hour after oral 
administration of the test compounds. Trunk blood was collected and centrifuged at 
1,600 g at 4°C for 20 minutes, and the supernatant was collected as plasma samples. The 
plasma prolactin concentration was determined using an EIA kit (RAT PROLACTIN 
ENZYME IMMUNOASSAY KIT A05101-96 Wells, SPI-bio Inc., France).  
3.11 Statistical analysis 
Data are expressed as mean ± standard error of the mean (S.E.M.). All statistical 
analyses were performed with SAS software (SAS Institute, Inc., Cary, NC, USA). For 
single measurement data, striatal cAMP and cGMP levels, total count of locomotor 
activity and plasma prolactin level, differences between the vehicle group and test 
compound-treated groups were compared by Dunnett’s multiple comparison test. For the 
CAR test, differences between the vehicle group and T-251 treated groups were compared 
using repeated measures analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test at each time point. For the PPI test, comparisons between the normal 
control (vehicle + saline) group and the deficit control (vehicle + MK-801) group or 
between the deficit control group and T-251 treated groups were performed by two-way 
ANOVA followed by Student’s t-test or Dunnett’s multiple comparison test. For NORT, 
comparisons between the normal control group and the deficit control group or between 
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the deficit control group and T-251 treated groups were performed by Student’s t-test or 
Dunnett’s multiple comparison test, respectively. The effect of clozapine, as a reference, 
was detected by Student’s t-test with comparison to the deficit control group. Both the 
training session and the test session were subjected to statistical analyses. All statistical 
analyses were performed using a two-tailed test with a significance level of 0.05. 
 
4 Results 
4.1 PDE selectivity 
T-251 showed a potent inhibitory effect against PDE10A with an IC50 value 
(95% CI) of 0.050 (0.038–0.067) nmol/L and showed high selectivity over other PDE 
families which had over 10,000-fold IC50 values (Table 1). These results indicate that 
T-251 is a potent and selective PDE10A inhibitor. 
Table 1. PDE selectivity of T-251.  
4.2 Effects of T-251 on striatal cAMP and cGMP levels 
To investigate oral bioactivity of T-251 for clinical application, striatal cAMP and 
cGMP levels were measured in mice after oral administration of T-251. T-251 (0.1, 0.3 
or 1.0 mg/kg) increased both cAMP and cGMP levels in a dose dependent manner 
(Figure 1A and 1B). High dose (1.0 mg/kg) of T-251 significantly increased both cAMP 
(P < 0.05) and cGMP levels (P < 0.01) in the striatum (Figure 1A and 1B). 
Subtypes Source of enzymes Substrates IC50 (nmol/L) 
PDE1 rat ventricle cGMP >10,000 
PDE2A human recombinant cGMP >10,000 
PDE3 canine heart cAMP >10,000 
PDE4 canine lung cAMP 1,700 
PDE5 canine lung cGMP 2,100 
PDE6 bovine retina cGMP 1,900 
PDE7B human recombinant cAMP >10,000 
PDE8A human recombinant cAMP >10,000 
PDE9A human recombinant cGMP >10,000 
PDE10A human recombinant cAMP 0.050 
PDE11A human recombinant cGMP 4,900 
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Figure 1. Effects of T-251 on the cAMP and cGMP level in the mouse striatum. 
Mice were sacrificed by focused microwave irradiation to the brain at 1 hour after oral administration of 
T-251 (0.1, 0.3 or 1.0 mg/kg) or vehicle. (A) Striatal cAMP levels were determined using EIA kit. 
(B) Striatal cGMP levels were measured using EIA kit. Data are expressed as mean ± S.E.M. (n = 7 or 8). 
*P < 0.05, **P < 0.01 compared with the vehicle group (Dunnett’s multiple comparison test). 
4.3 Effects of T-251 on spontaneous locomotor activity and MK-801 induced 
hyperactivity  
Oral administration of T-251 (0.09, 0.3, 1.0 or 3.0 mg/kg) decreased the spontaneous 
locomotor activity in rats in a dose dependent manner (Figure 2A). The ED50 value 
(95% CI) of T-251 for spontaneous locomotor activity was 0.94 (0.52–1.7) mg/kg. T-251 
(1.0 and 3.0 mg/kg) significantly (P < 0.01) decreased locomotor activity in rats (Figure 
2A). Furthermore, oral administration of T-251 (0.09, 0.3, 1.0 or 3.0 mg/kg) attenuated 
MK-801 induced hyperactivity in rats in a dose dependent manner (Figure 2B). The ED50 
value (95% CI) of T-251 for MK-801 induced hyperactivity was 0.68 (0.40–1.2) mg/kg. 
T-251 (1.0 and 3.0 mg/kg) significantly (P < 0.01) decreased MK-801 induced 
hyperactivity in rats (Figure 2B). 
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Figure 2. Effects of T-251 on spontaneous locomotor activity and MK-801 induced 
hyperactivity in rats.  
(A) Time-course and accumulative counts of spontaneous locomotor activity were measured for 20 minutes 
from 1 hour after oral administration of T-251 (0.09, 0.3, 1.0 or 3.0 mg/kg) or vehicle. Locomotor activity 
was measured as described in the method. (B) Time-course and accumulative counts of locomotor activity 
for 40 minutes from just after injection of MK-801 (0.075 mg/kg, s.c.) 1 hour after oral administration of 
T-251 (0.09, 0.3, 1.0, or 3.0 mg/kg) or vehicle. Data are expressed as mean ± S.E.M. (n = 8). **P < 0.01 
compared with the vehicle group (Dunnett’s multiple comparison test). 
4.4 Efficacy of T-251 in CAR test 
The effect of T-251 (0.3, 1.0 or 3.0 mg/kg) in the CAR test was investigated. To 
assess the changes of efficacy over time, the test was conducted at multiple time points 
within 24 hours. Oral administration of T-251 suppressed CAR in rats in a dose dependent 
manner (Figure 3). Repeated measures ANOVA revealed the significant effect of T-251 
(group: F3,36 = 36.81, P < 0.01; group × time: F15,180 = 16.16, P < 0.01). The inhibitory 
effect of T-251 on CAR peaked at 1 hour after oral administration and decreased in a 
time-dependent manner. The ID50 values (95% CI) of T-251 were 0.87 (0.67–1.1), 
1.2 (0.82–1.8) and 2.4 (1.7–3.4) mg/kg at 1, 3, 5 hours after administration, respectively. 
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At higher doses exceeding ID50 values for each time point, T-251 showed increase of 
escape failures (Table 2). The largest percentage of escape failures (40.5 ± 9.9 %) was 
seen at 1 hour after administration of T-251 (3.0 mg/kg). 
 
Figure 3. Inhibitory effects of T-251 on CAR in rats. 
The test sessions were conducted at 1, 3, 5, 7 and 24 hours after the oral administration of T-251 (0.3, 1.0 
or 3.0 mg/kg) or vehicle. Data are expressed as mean ± S.E.M. (n = 10). *P < 0.05, **P < 0.01 compared 
with the vehicle group (repeated measures ANOVA followed by Dunnett’s multiple comparison test). 
Table 2. Escape failure on each time point in CAR test for T-251. 
Data are expressed as the mean ± S.E.M. (n = 10). 
4.5 Effect of T-251 on MK-801 induced PPI deficits in rats 
The effects of T-251 (1.0, 3.0 and 10 mg/kg) on MK-801 induced PPI deficits in rats 
was investigated. Two-way ANOVA revealed the significant difference between the 
normal control group and the deficit control group (group: F1,18 = 44.56, P < 0.01, 
prepulse intensity: F2,36=16.32, P < 0.01, group × prepulse intensity: F2,36 = 2.69, 
P = 0.08) and significant effect of T-251 (group: F3,38 = 6.73, P < 0.01, prepulse intensity: 
F2,76 = 97.18, P < 0.01, group × prepulse intensity: F6,76 = 1.21, P = 0.31). By following 
post-hoc test at each prepulse intensity, T-251 (3.0 and 10 mg/kg) significantly attenuated 
MK-801 induced PPI deficits at 85 dB and 90 dB (P < 0.01), but not 80 dB (Figure 4). 
 Escape failures (%) 
 Pre 1 h 3 h 5 h 7 h 24 h 
Vehicle 0 0 0 0 0 0 
0.3 mg/kg 0 0 0 0 0 0 
1.0 mg/kg 0 10.5 ± 5.6 0 0 0 0 
3.0 mg/kg 0 40.5 ± 9.9 14.0 ± 5.8 4.0 ± 3.1 0 0 
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Figure 4. Effect of T-251 on MK-801 induced PPI deficits in rats. 
PPI at three different prepulse intensity levels (80, 85 and 90 dB). Rats were orally administrated T-251 
and subcutaneously injected MK-801 (0.075 mg/kg), 1 hour and 25 minutes before the test starts, 
respectively. Data are expressed as mean ± S.E.M. (n = 10 or 11). ##P < 0.01 compared with the normal 
control (vehicle + saline) group (two-way ANOVA followed by Student’s t-test), **P < 0.01 compared 
with the deficit control (vehicle + MK-801) group (two-way ANOVA followed by Dunnett’s multiple 
comparison test). 
4.6 Effect of T-251 on MK-801 induced cognitive deficits in rats 
In the training session, there were no statistical differences among all groups. Similar 
to clozapine (3.0 mg/kg), T-251 (0.6 mg/kg) significantly (P < 0.05) attenuated MK-801 
induced cognitive deficits in rats (Figure 5).  
 
Figure 5. Effect of T-251 on MK-801 induced cognitive deficits in NORT in rats. 
Rats were orally administrated the test compounds (T-251 and clozapine, as the reference) 1 hour prior to 
intraperitoneal injection of MK-801 (0.05 mg/kg). The training session was conducted 10 minutes after 
MK-801 injection and interval between the training session and the test session was 2 hours. Data are 
expressed as mean ± S.E.M. (n = 10 or 11). ##P < 0.01 compared with the normal control group (Student’s 
t-test), *P < 0.05 (Dunnett’s multiple comparison test) and +P < 0.05 (Student’s t-test), as compared with 
the deficit control group. N.S.: No significant differences were detected in the training session. 
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4.7 Effect of T-251 on catalepsy 
To assess the potency of T-251 for extrapyramidal side effects, the catalepsy test 
was performed (Figure 6). Haloperidol, olanzapine and clozapine were used as reference 
drugs. All drugs were evaluated at excess doses rather than their pharmacological 
effective doses; the highest dose was set at 5-fold or more than each ED50 value in the rat 
CAR test (data of reference drugs are not shown). Since typical antipsychotics were 
reported to elicit persistence catalepsy after acute administration in rats (Gyertyan et al., 
2011; Morimoto et al., 2002), the test was conducted up to 7 hours. T-251 (1.0–30 mg/kg) 
did not elicit catalepsy, whereas haloperidol and olanzapine elicited longer catalepsy, 
with ED10s values (95% CI) of 0.67 (0.41–0.91) mg/kg and 10.6 (0.0000024–24.5) mg/kg, 
respectively. Contrastively, clozapine (10–100 mg/kg) did not induce catalepsy in rats. In 
this study, we did not calculate ED10s values of T-251 and clozapine. 
A B 
  
C D 
 
Figure 6. Effects of T-251 (A), haloperidol (B), olanzapine (C) and clozapine (D) on 
cataleptogenic activity in rats.  
Catalepsy time was measured by the bar test (7-cm height, cut-off time = 60 sec). Measurement points were 
1, 3, 5 and 7 hours after the oral administration of the test compounds. Data are expressed as mean ± S.E.M. 
(n = 8). ED10s were calculated from total catalepsy time using liner regression analysis. N.C.: not calculated. 
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4.8 Effect of T-251 on plasma prolactin levels 
Treatment with antipsychotics can be associated with hyperprolactinemia, which 
may be associated with a wide variety of side effects. To assess the potency of T-251 on 
induction of hyperprolactinemia, plasma levels of prolactin were measured (Figure 7). 
Haloperidol and olanzapine were used as reference drugs. All drugs were evaluated at a 
pharmacological effective dose and a 10-fold higher dose. Haloperidol and olanzapine 
showed significant increase in plasma prolactin levels at 1 hour after a single oral 
administration. In contrast, T-251 (0.6 and 6.0 mg/kg) did not increase plasma levels of 
prolactin in rats.  
 
Figure 7. Effect of T-251, haloperidol and olanzapine on plasma prolactin levels in 
rats.  
Rats were sacrificed after 1 hour after oral administration of the test compounds. The plasma prolactin 
concentrations were measured using EIA kit. Data are expressed as mean ± S.E.M. (n = 5). * P <0.05, 
**P < 0.01 compared with the vehicle group (Dunnett’s multiple comparison test). 
5 Discussion 
In the last decade, clinical trials for several PDE10A inhibitors in patients with 
schizophrenia have been conducted. In a proof-of-concept (POC) study, MP-10 
(PF-02545920) did not show beneficial effects compared to placebo (DeMartinis et al., 
2019). Another PDE10A inhibitor TAK-063 (Balipodect) also did not achieve its primary 
endpoint (statistically significant difference in PANSS total score change compared with 
placebo at 6 weeks of treatment). However, some evaluation scales were ameliorated by 
TAK-063 (Macek et al., 2019), suggesting the efficacy of PDE10A inhibitors in 
schizophrenia could be demonstrated by stratifying patients. In both POC studies, 
although adverse events such as dystonia, akathisia and somnolence occurred, they were 
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mild or moderate. Interestingly, TAK-063 showed fast off-rate from PDE10A compared 
to MP-10, and exerted different activation balances for D1-type and D2-type neurons 
(Suzuki et al, 2016; Suzuki and Kimura, 2018). These data suggest that PDE10A 
inhibitors with different off-rates may have different profiles for efficacy and adverse 
effects. 
In this study, we demonstrated the pharmacological profile of T-251, a PDE10A 
inhibitor with a different chemical structure from MP-10 or TAK-063 (Kadoh et al., 2018) 
in rodents. T-251 showed significant antipsychotic-like effects with less side effects seen 
by dopamine D2 receptor antagonists, similar to MP-10 and TAK-063. 
T-251 showed potent inhibitory activity of PDE10A and high selectivity over other 
PDE families which have IC50 ratios of over 10,000 compared to PDE10A. An oral single 
administration of T-251 (1.0 mg/kg) significantly increased cAMP and cGMP levels in 
the striatum, indicating that T-251 causes PDE10A inhibition in the striatum after oral 
administration.  
(+)-MK-801 has been used to cause schizophrenia-like behavioral abnormalities in 
rodents (Cadinu et al., 2018; Gobira et al., 2013). In this study, the ED50 value of T-251 
for MK-801 induced hyperactivity was 0.68 mg/kg (p.o.). In contrast, T-251 significantly 
attenuated spontaneous activity in rats. Since the ED50 value of T-251 for spontaneous 
activity was 0.94 mg/kg, it seems that T-251 induced sedation may, in part, contribute to 
attenuation of MK-801 induced hyperlocomotion by T-251. The CAR test is widely used 
to predict antipsychotic-like effects in humans since the potency of dopamine D2 blocking 
antipsychotics observed in the CAR test correlates well with antipsychotic effects in 
humans (Wadenberg, 2010). T-251 showed the highest efficacy at 1 hour after oral 
administration with an ID50 value of 0.87 mg/kg. The effect of T-251 continued for up to 
5 hours. In addition, T-251 (3.0 and 10 mg/kg, p.o.) significantly attenuated MK-801 
induced PPI deficits in rats although these doses of T-251 were higher than the ED50 
(0.68 mg/kg) for MK-801 induced hyperactivity. 
Cognitive impairment in schizophrenia is a core symptom (Elvevag and Goldberg, 
2000). The antipsychotics currently in use have limited beneficial effects for cognitive 
impairment in schizophrenia. In the NORT, like clozapine (3.0 mg/kg, p.o.), T-251 
(0.6 mg/kg, p.o.) significantly improved MK-801 induced cognitive deficit in rats. These 
results suggest that T-251 may have beneficial effect for cognitive impairment in patients 
with schizophrenia. 
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Finally, we investigated the side effect profile of T-251 in rats. EPS are the most 
major and serious adverse effects induced by current antipsychotics, leading to treatment 
withdrawal (Kane, 2001). Unlike haloperidol and olanzapine, T-251 and clozapine did 
not produce catalepsy at higher doses. In addition, T-251 did not increase plasma levels 
of prolactin 1 hour after a single administration whereas haloperidol or olanzapine 
significantly increased them. Collectively, T-251 may be an antipsychotic with fewer side 
effects than current antipsychotics. 
In this study, the efficacy of T-251 on negative symptoms of schizophrenia was not 
evaluated. Several other PDE10A inhibitors have been reported to be effective for 
negative symptoms in rodents (Grauer et al., 2009; Langen et al., 2012). These 
compounds are also reported to be effective for cognitive dysfunction in addition to 
positive symptoms and have fewer side effects compared to current antipsychotics. Thus, 
it is likely that T-251 may also be effective against negative symptoms, although further 
studies in animal models for negative symptoms are needed.  
As described, clinical trials for PDE10A inhibitors for schizophrenia have so far 
been unsuccessful, but different compounds have shown different profiles for efficacy 
and side effects. The potential of PDE10A inhibitors for schizophrenia is still being 
explored; clinical trials for another PDE10A inhibitor, Lu AF11167, for the treatment of 
schizophrenia negative symptoms are now undergoing (clinicaltrials.gov, NCT03793712 
and NCT03929497). T-251 is also anticipated to lead the way for PDE10A inhibitors as 
potential treatments for schizophrenia. 
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III. CHAPTER 2 
ANTIPSYCHOTIC-LIKE EFFECTS OF A NOVEL 
PHOSPHODIESTERASE 10A INHIBITOR MT-3014 
 
1 Abstract 
Phosphodiesterase (PDE) 10A is an attractive target for the treatment of 
schizophrenia. Here we investigated the antipsychotic-like effects of a novel PDE10A 
inhibitor, 1-({2-(7-Fluoro-3-methylquinoxalin-2-yl)-5-[(3R)-3-fluoropyrrolidin-1-
yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)-2-methylpropan-2-ol hydrochloride (MT-
3014). MT-3014 showed a potent and selective inhibitory effect against PDE10A 
(IC50 = 0.357 nmol/L). Oral administration of MT-3014 (1.0–10 mg/kg) significantly 
increased the levels of cAMP, cGMP and cAMP response element-binding protein 
(CREB) phosphorylation in the rat striatum. MT-3014 decreased MK-801 (0.075 mg/kg)-
induced hyperactivity (ED50 = 0.30 mg/kg), in a dose dependent manner, although 
spontaneous locomotion was also decreased in control rats (ED50 = 0.48 mg/kg). MT-
3014 (0.3–3.0 mg/kg and 0.2 mg/kg) attenuated MK-801-induced prepulse inhibition 
deficits and cognitive deficits in rats. Furthermore, MT-3014 (0.25–1.0 mg/kg) 
suppressed conditioned avoidance response (CAR, ID50 = 0.52 mg/kg). MT-3014 did not 
elicit catalepsy and plasma prolactin increase at excess doses of the pharmacological dose, 
nor affect the body weight at the pharmacological dose, whereas risperidone or olanzapine 
did. A positron emission tomography study using [11C]IMA107 showed a plasma 
concentration-dependent increase of brain PDE10A occupancy after oral administration 
of MT-3014 in the pharmacological dose range. These results show that MT-3014 may 
be an antipsychotic drug without side effects associated with the current atypical 
antipsychotics. 
  
23 
 
2 Introduction 
Schizophrenia is a complex psychiatric disorder primarily characterized by positive 
symptom, negative symptom and cognitive impairment (Owen et al., 2016). Typical 
antipsychotics are highly effective against positive symptoms but less against negative 
symptoms and cognitive impairment, and are accompany by side effects such as 
extrapyramidal symptoms (EPS) and hyperprolactinemia (De Hert et al., 2016; Kane, 
2001). Atypical antipsychotics have partial effects on negative symptoms and cognitive 
impairment through broader mechanism of actions, such as partial agonism of the D2 
receptor, dual dopamine/serotonin blockage and multiple receptor blockage. Atypical 
antipsychotics have had success in reducing side effects caused by typical antipsychotics, 
but have been reported to cause other side effects such as weight gain and increased risk 
of diabetes (Leucht et al., 2009; Serretti et al., 2004; Tschoner et al., 2007). New classes 
of drugs that show more effect against symptoms for which current antipsychotics lack 
potency, or have better side effect profiles are desired (Citrome, 2014; Forray and Buller, 
2017; Krebs et al., 2006). Phosphodiesterase (PDE)10A inhibitors are one of the 
candidates for novel antipsychotics (Kehler and Nielsen, 2011; Krogmann et al., 2019; 
Swierczek et al., 2019). 
PDE10A is highly expresses in medium spiny neurons (MSN) of the striatum 
(Fujishige et al., 1999; Seeger et al., 2003; Soderling et al., 1999) and hydrolyzes both 
cAMP and cGMP. The striatum is a region in which much information is integrated, 
including glutamatergic input from the cortex and dopaminergic input from the ventral 
tegmental area or the substantia nigra (Graybiel, 1990, 2000). Outputs from the striatum 
are mainly divided into the direct pathway from D1-expressing neurons and the indirect 
pathway from D2-expressing neurons and are then reintegrated (Surmeier et al., 2007). 
Inhibition of PDE10A activates both direct and indirect pathways via upregulation of 
cAMP in both types of neurons, that is, PDE10A inhibitors could have a dual D1 agonist 
and D2 antagonist like effect (Siuciak et al., 2006b). PDE10A inhibitors are expected to 
provide a new therapeutic approach for schizophrenia by rescuing weakened cortical 
glutamatergic input which seems to be associated with negative symptoms and cognitive 
symptoms in addition to the antipsychotic effect of D2 blockage (Siuciak et al., 2006a; 
Siuciak et al., 2006b; Snyder and Vanover, 2014, 2017). Moreover, PDE10A inhibitors 
are expected to avoid side effects caused by current antipsychotics via excess activation 
of the indirect pathway, by also activating the direct pathway in a balanced manner. 
Indeed, several PDE10A inhibitors have been developed for treatment of schizophrenia 
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in the last decade (Arakawa et al., 2016; Geerts et al., 2017; Grauer et al., 2009; Kehler, 
2013; Suzuki et al., 2015; Takakuwa et al., 2019; Zagorska et al., 2018). 
In this study, we investigated the antipsychotic-like profiles of a novel PDE10A 
inhibitor, 1-({2-(7-Fluoro-3-methylquinoxalin-2-yl)-5-[(3R)-3-fluoropyrrolidin-1-
yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)-2-methylpropan-2-ol hydrochloride (MT-3014, 
Koizumi et al., 2019) in rats. Furthermore, we examined the receptor occupancy of 
PDE10A in the brain after oral administration of MT-3014. 
 
3 Materials and Methods  
3.1 Animals  
Male Wistar rats (5-9 weeks old, Japan Charles River Inc., Yokohama, Japan) were 
used for measurement of striatal cAMP and cGMP levels, measurement of cAMP 
response element-binding protein (CREB) phosphorylation levels and the conditioned 
avoidance response (CAR) test. Male Wistar rats (7-10 weeks old, Japan SLC, Inc., 
Hamamatsu, Japan) were used for the locomotor activity tests, prepulse inhibition (PPI) 
test, catalepsy test and measurement of plasma prolactin levels. Male Long-Evance rats 
(7–8 weeks old, Institute for Animal Reproduction, Ibaraki, Japan) were used for the 
novel object recognition test (NORT). Female Crl:CD (SD) rats (8 weeks old at the start, 
Japan Charles River Inc., Yokohama, Japan) were used for measurement of body weight 
change. Male Wistar rats (8-16 weeks old, Charles River Ltd., Margate, UK) were used 
for the positron emission tomography (PET) study. 
All animals were housed under environmentally controlled conditions; 12-h 
light/dark cycle (lights on at 7:00 AM), temperature: 20–26°C, humidity: 26–70% with 
access to food and water ad libitum. All in vivo experimental procedures were approved 
by the Institutional Animal Care and Use Committee of Research Laboratories in 
Mitsubishi Tanabe Pharma Corporation (MTPC) or corresponding organizations of the 
testing facilities. 
3.2 Test compounds 
MT-3014 was synthesized at MTPC (Yokohama, Japan). MT-3014 was dissolved in 
dimethyl sulfoxide (DMSO) for the in vitro PDE assay and off-target study or suspended 
in 0.5% (hydroxypropyl)methyl cellulose (HPMC)–0.1% Tween 80 (vehicle) for in vivo 
studies. Risperidone and olanzapine, used as reference drugs, were also synthesized at 
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MTPC and suspended in the same vehicle. [11C]IMA107 was synthesized at Imanova Ltd. 
(London, UK) from a precursor provided from MTPC (Plisson et al., 2014). [11C]IMA107 
was dissolved in 10% ethanol in saline. (+)-MK-801 hydrogen maleate (MK-801) was 
purchased from Sigma-Aldrich, Inc. (St. Louise, MO, USA) and dissolved in saline. 
3.3 In vitro PDE assay 
Human recombinant PDE1A3, 2A3, 3A, 4D3, 5A1, 6AB, 7B, 8A1, 9A1, 10A2 and 
11A1 were purchased from SB drug discovery, Ltd. (Glasgow, Scotland, UK).  
The PDE assay was performed by the radio-labeled nucleotide method modified 
from the method of Thompson et al., 1979. Briefly, MT-3014, enzymes, substrates 
(approximate 15 nmol/L Adenosine 3’,5’-cyclic phosphate, ammonium salt, [2,8-3H]-, or 
32 nmol/L Guanosine 3’,5’-cyclic monophosphate, ammonium salt, [8-3H]-: PerkinElmer, 
Inc., Waltham, MA, USA) were mixed in assay buffer (50 mmol/L Tris-HCl, pH 8.0, 
5 mmol/L MgCl2, 4 mmol/L 2-mercaptoethanol and 0.33 mg/mL bovine serum albumin) 
and incubated at 37°C for 30 minutes. The reaction was stopped by boiling, then 
0.167 mg/mL snake venom were added, and the mixtures were incubated at 37°C for 
another 30 min. The reaction was stopped by boiling, and an approximately equivalent 
volume of methanol was added. Resultant solutions were applied to a Dowex (1 × 8 200–
400) resin filter and then washed with methanol. The radioactivity of eluates was 
measured with a liquid scintillation counter (2500, PerkinElmer, Inc., Waltham, MA, 
USA). The IC50 values were calculated by the logit-log model using logarithmic 
concentrations and % inhibition. 
3.4 Off-target study 
Binding assays for primary 52 target proteins (enzymes, ion channels, receptors and 
transporters) were performed using in vitro profiling panel at Eurofins Panlabs Discovery 
Services Taiwan, Ltd. (Taipei, Taiwan). 
3.5 Measurement of striatal cAMP and cGMP levels 
Three hours after oral administration of MT-3014 (0.3, 1.0, 3.0 or 10 mg/kg), rats 
were sacrificed by focused microwave irradiation to the brain. The striatum was isolated 
and homogenized in 1% Triton-X-100/phosphate buffered salts on ice and centrifuged at 
21,600 g at 4°C for 5 minutes. The concentrations of cAMP and cGMP in supernatants 
were measured using enzyme immunoassay (EIA) kits (Cat. No. RPN225 and RPN 226, 
GE Healthcare UK Limited, Buckinghamshire, UK).  
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3.6 Measurement of CREB phosphorylation level 
One hour after oral administration of MT-3014 (0.3, 1.0, 3.0 or 10 mg/kg), rats were 
sacrificed by focused microwave irradiation to the brain. The striatum was isolated and 
homogenized in cell extraction buffer (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) including protease inhibitor and phosphatase inhibitor cocktails, sonicated on ice, 
and centrifuged at 16,000 g at 4°C for 15 minutes. The concentrations of phosphorylated 
CREB (pCREB, pS133) and total CREB in supernatants were measured using EIA kits 
(Cat. No. KHO0241 and KHO0231, Thermo Fisher Scientific Inc., Waltham, MA, USA). 
CREB phosphorylation levels were determined as the ratio of pCREB to total CREB in 
each rat. 
3.7 Measurement of locomotor activity 
Locomotor activity of rats were measured in polymethylpentene cages (22 × 38 × 
19.5 cm) set in the SCANET system (SV-40®, MELQUEST Ltd., Toyama, Japan). 
MT-3014 (0.1, 0.3, 1.0 or 3.0 mg/kg) was orally administered to rats 1 hour prior to 
measurements. For measurement of MK-801-induced hyperactivity, MK-801 
(0.075 mg/kg) was subcutaneously injected just before the measurement. Locomotor 
activity was measured as the number of crossing the horizontal infrared light beam for 
20 minutes for spontaneous activity or for 40 minutes for MK-801-induced hyperactivity. 
The ED50 values and their 95% confidence intervals (CI) were estimated from total counts 
by non-liner regression analysis. 
3.8 PPI test 
PPI tests were conducted using SR-LAB® acoustic startle chambers (San Diego 
Instruments, San Diego, CA, USA), each equipped with a clear, nonrestrictive Plexiglas 
cylinder, in a sound-attenuated chamber. A loudspeaker inside each chamber provided 
background noise of 70 dB continuously. Rats placed inside the cylinders are stimulated 
with acoustic stimuli, triggering the whole-body startle response, which is detected by 
transducing movement into analog signals by a piezoelectric unit attached to the platform.  
The session consisted of five different trials; (1) PULSE ALONE trial 
(40 milliseconds, 120 dB), (2–4) PREPULSE trial (20 millisecond prepulses at 80, 85 or 
90 dB and 40 milliseconds PULSE 100 milliseconds after prepulse) and (5) NOSTIM 
trial (only the background noise) conducted in a pseudorandom order with an interval of 
12–18 seconds. Each trial was conducted 12 times. The startle responses were averaged 
excluding the first time of each trial. PPI was calculated using the following formula: 
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PPI (%) = 100-[{(PREPULSE-NOSTIM) / (PULSE ALONE-NOSTIM)} *100]. Based 
on the results from the baseline session on the day before the test, rats which showed 10–
299 responses in the PULSE ALONE trial and > 40% PPI (the average of PPI at 80, 85 
and 90 dB) were selected. In the test session, MT-3014 (0.3, 1.0 or 3.0 mg/kg) were orally 
administered 1 hour before the start of the test. MK-801 (0.075 mg/kg) was 
subcutaneously injected 25 minutes before the start of the test. 
3.9 NORT 
NORT was performed in a test box (45.5 × 25 × 35 cm) set in the SCANET system 
(MV-10AQ®, MATYS Co., Tokyo, Japan). Two objects; a brown glass conical flask (vol. 
100 mL, dia. 6.5 cm, height 10.3 cm) and a white polystyrene bottle (dia. 6.2 cm, height 
12.4 cm) were set in two adjacent corners in-touch of the walls of the test box. 
On the day before the test day, rats were habituated to the test box for 5 minutes. On 
the test day, MT-3014 (0.1 or 0.2 mg/kg) were orally administered 1 hour prior to 
intraperitoneal injection of MK-801 (0.1 mg/kg). The training session was conducted 
10 minutes after MK-801 injection where rats were exposed to two identical objects for 
5 minutes. The test session was conducted 2 hours after the training session where rats 
were exposed to two objects for 5 minutes with one object replaced by a novel one. Object 
exploration was defined as the rats sniffing, licking, touching or biting. Exploration 
preference was calculated using the following formula: Exploration preference (%) = 
(time spent exploring the novel object) / (the total exploration time of the two objects) × 
100. 
3.10 CAR test 
Conditioned avoidance behavior was assessed using automated shuttle-boxes (56 × 
21 × 25 cm, MSB-001, MELQUEST Ltd., Toyama, Japan) each placed in a sound-
attenuated chamber. The boxes were subdivided into two compartments by a partition 
with one opening. The position of rats and their movement from one compartment to the 
other were detected by photocells sensitive to infrared light on each side of the partition. 
A session consisted of 20 trials with 10 second inter-trial intervals. Each trial 
consisted of a 5 second tone (conditioned stimulus, CS) followed by a 10 second tone 
plus mild electric stimulus (0.8 mA, unconditioned stimulus, UCS) being applied to the 
grid floor. If the rat moved from one compartment to the other, the stimulus was 
immediately terminated. The following behavioral variables were recorded: avoidance 
(response to CS within 5 seconds), escape failures (failure to respond to UCS). Rats were 
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trained as described above, and only rats which showed a high level of avoidance response 
(at least 80%) on three consecutive days were used for evaluation of MT-3014 using the 
same protocol.  
On the test day, following the pre-test, rats were orally administered with MT-3014 
(0.25, 0.5 or 1.0 mg/kg) and tested 1, 3, 5, 7 and 24 hours later. Avoidance response (%) 
and escape failure (%) at each time point was calculated. The ID50 values and its 95% CI 
for avoidance response at each time point were estimated by non-liner regression analysis. 
In addition, the inhibition rate (%) at each time point was calculated using the following 
formula: Inhibition (%) = 100 - [(avoidance rate at each timepoint) / (avoidance rate at 
pre-test)] × 100]. 
Blood samples were collected into heparinized tubes from the tail vein of satellite 
animals at 1, 3, 5, 7 and 24 hours after oral administration of MT-3014 (0.25, 0.5 and 
1 mg/kg). The plasma was obtained, and MT-3014 concentration in plasma was 
determined using liquid chromatography tandem mass spectrometry (LC-MS/MS). 
Inhibition (%) against corresponding plasma MT-3014 concentration was plotted, 
and the EC50 value and its 95% CI was estimated by non-liner regression analysis. 
3.11 Catalepsy 
Rats were orally administered with MT-3014 (1.0, 3.0, 10 or 30 mg/kg) or 
risperidone (5.0, 10, 25 or 50 mg/kg) and tested 1, 3, 5 and 7 hours later for catalepsy by 
the bar test (Morimoto et al., 2002). Forepaws of the rats were placed on a 7 cm-high bar 
and recorded for how long they retained the same position in a blinded manner. The 
maximum measurement time (cut-off time) was 60 sec at each time point. The effective 
dose of 10 seconds (ED10s value) and its 95% CI for each compound was estimated from 
the total catalepsy time of four time points by non-linear regression analysis. 
3.12 Measurement of plasma prolactin level 
One hour after oral administration of MT-3014 (3.0 or 10 mg/kg) or risperidone 
(1.0 or 3.0 mg/kg), rats were sacrificed by decapitation under non-anesthesia. Trunk 
blood was collected and centrifuged at 1,600 g at 4°C for 15 minutes, and the supernatant 
was collected as plasma samples. The plasma prolactin concentration was determined 
using an EIA kit (RAT PROLACTIN ENZYME IMMUNOASSAY KIT A05101-
96 Wells, SPI-bio Inc., France).  
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3.13 Measurement of body weight change 
Rats were orally administrated with MT-3014 (0.1, 0.3 or 1.0 mg/kg) or olanzapine 
(3.0 mg/kg), and their body weight was measured once a day for 3 weeks. Body weight 
changes from the first day (day0) of each individual were calculated. 
3.14 PET imaging study  
PET imaging studies were conducted according to the method of (Plisson et al., 
2014). Briefly, three [11C]IMA107 PET scans were performed on each animal under 
isoflurane anesthesia; one was scanned under the baseline condition, and the second and 
the third scans was performed after intravenous injection of MT-3014 (0.02–6.0 mg/kg). 
Each animal was injected [11C]IMA107 (15.2 ± 3.0 MBq) via the tail vein cannula, and 
immediately received dynamic PET scans for 60 or 90 min. Inveon DPET with a docked 
multi-modality computed tomography (CT) scanner (Siemens Healthcare, Erlangen, 
German) was used. A CT scan was acquired covering the PET field of view (up to 
108 mm long) and the structural data acquired was used to facilitate region of interest 
drawing. Dynamic PET images were acquired in list mode with increasing frame times 
over the duration of the scan to characterize the radiotracer kinetics. Fourier rebinning 
was performed and images were reconstructed using a two-dimensional filtered back 
projection (2D FBP) algorithm and a ramp filter to generate images on a 128 × 128 matrix 
(Bao et al., 2009).  
Radioactive concentrations in the tissue were normalized by injected dose (% of 
injected dose/L). Using the simplified reference tissue model (SRTM, Lammertsma and 
Hume, 1996) with the cerebellum as the reference region, the nondisplaceable binding 
potential (BPND) which is proportional to target availability, was calculated for the 
striatum. Target occupancy was calculated as the percent reduction in BPND from the 
baseline following administration of MT-3014: Occupancy (%) = 100 × (BPND baseline - 
BPND postdose) / BPND baseline. 
Blood samples of the animals were obtained during PET scans, and plasma 
concentrations of MT-3014 were determined according to section 3.10. Occupancy (%) 
against corresponding plasma MT-3014 concentrations was plotted, and the EC50 value 
and its 95% CI was estimated by non-liner regression analysis. 
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3.15 Statistical analysis 
Data are expressed as mean ± standard error of the mean (S.E.M.) for in vivo 
pharmacological studies or as mean ± standard deviation (S.D.) for measurement of 
plasma MT-3014 concentration. 
For measurement of striatal cAMP, cGMP CREB phosphorylation levels, plasma 
prolactin levels and spontaneous locomotor activity, differences between the vehicle 
group and test compounds-treated groups were assessed by Dunnett’s multiple 
comparison test. For MK-801-induced hyperactivity test and NORT, differences between 
the vehicle group the normal control (vehicle + saline) group and the deficit control 
(vehicle + MK-801) group or between the deficit control group and MT-3014-treated 
groups were assessed by Student’s t-test or Dunnett’s multiple comparison test, 
respectively. For the PPI test, two-way analysis of variance (ANOVA) was used to detect 
the effect of MK-801 compared to normal control group or the effect of MT-3014 
compared to the deficit control group, and Student’s t-test or Dunnett’s multiple 
comparison test were used as the post-hoc tests, respectively. For the CAR test, catalepsy 
test (time-course data) and measurement of body weight change, repeated measures 
ANOVA was used to detect the effect of each test compound compared to the vehicle 
group, and Dunnett’s multiple comparison test or student’s t-test were used as the post-
hoc test for MT-3014 and risperidone or olanzapine, respectively.  
All statistical analyses were performed with SAS software (SAS Institute, Inc., Cary, 
NC, USA) using a two-tailed test with a significance level of 0.05. 
 
4 Results  
4.1 In vitro profiling of MT-3014 
MT-3014 showed a potent inhibitory effect against PDE10A with an IC50 value 
(95% CI) of 0.357 (0.131–0.976) nmol/L (Table 1). MT-3014 showed good selectivity 
over other PDE families which had over 500-fold IC50 values (Table 1) and over other 
52 primary target proteins (enzymes, ion channels, receptors and transporters related to 
central nervous systems) which had over 1000-fold IC50 values (data not shown). 
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Table 1. PDE selectivity of MT-3014.  
4.2 Oral bioactivity of MT-3014 in rats 
The oral bioactivity of MT-3014 was investigated. Oral administration of MT-3014 
increased striatal cAMP and cGMP levels, which are both substrates of PDE10A 
(Figure 1A and 1B). MT-3014 increased CREB phosphorylation, a downstream signal 
of cAMP (Figure 1C). Statistically significant increase of all cAMP, cGMP and pCREB 
were observed at a dose of 1.0 mg/kg or more (P < 0.01, Figure 1). 
Subtypes Substrates IC50 (nmol/L) 95% CI 
PDE1A3 cGMP > 10,000 - 
PDE2A3 cAMP > 10,000 - 
PDE3A cAMP > 10,000 - 
PDE4D3 cAMP 343 270–434 
PDE5A1 cGMP 564 422–755 
PDE6AB cGMP 7,550 4,220–13,500 
PDE7B cAMP 7,680 1,920–30,800 
PDE8A1 cAMP > 10,000 - 
PDE9A1 cGMP > 10,000 - 
PDE10A2 cAMP 0.357 0.131–0.976 
PDE11A1 cAMP 3,690 2,170–6,290 
CI: confidence interval 
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Figure 1. Effect of MT-3014 on striatal cAMP (A), cGMP (B) and CREB 
phosphorylation (C) levels in rats 
The cAMP (A), cGMP (B) and CREB phosphorylation (C) levels were measured in microwave-irradiated 
striatum. MT-3014 (0.3, 1.0, 3.0 or 10) or vehicle were orally administrated 3 (A and B) or 1 (C) hours 
before sacrifice. Data are expressed as mean ± S.E.M. (A and B: n = 10–12, C: n = 8). **P < 0.01 compared 
with the vehicle group (Dunnett’s multiple comparison test). 
4.3 Effects of MT-3014 on spontaneous locomotor activity and MK-801-
induced behavioral abnormalities 
To assess the antipsychotic-like effects of MT-3014 in rats, several behavioral tests 
were conducted. Oral administration of MT-3014 decreased spontaneous locomotor 
activity, and statistical significances were detected at a dose of 1.0 mg/kg or more 
(Figure 2A). The ED50 value (95% CI) of MT-3014 for spontaneous locomotor activity 
was 0.48 (0.35–0.66) mg/kg. MT-3014 attenuated MK-801 (0.075 mg/kg)-induced 
hyperactivity in rats, in a dose dependent manner (Figure 2B). The ED50 value (95% CI) 
of MT-3014 for MK-801-induced hyperactivity was 0.30 (0.20–0.44) mg/kg. 
Effects of MT-3014 on MK-801-induced PPI deficits in rats were examined. In MK-
801-induced PPI deficits, two-way ANOVA revealed the significant effect of MT-3014 
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(group: F3,37 = 5.69, P < 0.01, prepulse intensity: F2,74 = 50.22, P < 0.01, group × prepulse 
intensity: F6,74 = 1.81, P = 0.11). By following post-hoc test at each prepulse intensity, 
MT-3014 (0.3–3.0 mg/kg) significantly attenuated MK-801-induced PPI deficits at 90 dB 
(P < 0.01), and MT-3014 (1.0 mg/kg) did at 85 dB (P < 0.05, Figure 2C). 
Effects of MT-3014 on MK-801-induced cognitive deficits in rats were examined. 
In NORT, MT-3014 (0.2 mg/kg), but not 0.1 mg/kg, significantly improved MK-801-
induced cognitive deficits in rats (P < 0.05, Figure 2D).  
A B 
      
C D 
 
Figure 2. Effects of MT-3014 on spontaneous locomotor activity and MK-801- 
induced abnormal behaviors in rats.  
(A): Spontaneous locomotor activity was measured for 20 minutes from 1 hour after oral administration of 
MT-3014 (0.1, 0.3, 1.0 or 3.0 mg/kg) or vehicle. Locomotor activity was measured as the number of 
crossing the horizontal infrared light beam. Data are expressed as mean ± S.E.M. (n = 10). **P < 0.01 
compared with the vehicle group (Dunnett’s multiple comparison test). (B): Locomotor activity for 
40 minutes from just after injection of MK-801 (0.075 mg/kg, s.c.) 1 hour after oral administration of 
MT-3014 (0.1, 0.3, 1.0 or 3.0 mg/kg) or vehicle. Locomotor activity was measured as the number of 
crossing the horizontal infrared light beam. Data are expressed as mean ± S.E.M. (n = 10). ##P < 0.01 
compared with the normal control (vehicle + saline) group (Student’s t-test), **P < 0.01 compared with the 
deficit control (vehicle + MK-801) group (Dunnett’s multiple comparison test). (C): PPI at three different 
prepulse intensity levels (80, 85 and 90 dB) was measured 1 hour and 25 minutes after oral administration 
of MT-3014 (0.3, 1.0 or 3.0 mg/kg) and subcutaneously injection of MK-801 (0.075 mg/kg), respectively. 
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Data are expressed as mean ± S.E.M. (n = 10–11). ##P < 0.01 compared with the normal control group (two-
way ANOVA followed by Student’s t-test), *P < 0.05 and **P < 0.01 compared with the deficit control 
group (two-way ANOVA followed by Dunnett’s multiple comparison test). (D): In NORT, rats were orally 
administrated MT-3014 (0.1 or 0.2 mg/kg) or vehicle 1 hour prior to intraperitoneal injection of MK-801 
(0.1 mg/kg). The training session was conducted 10 minutes after MK-801 injection and interval between 
the training session and the test session was 2 hours. Data are expressed as mean ± S.E.M. (n = 9–10). 
##P < 0.01 compared with the normal control group (Student’s t-test), *P < 0.05 compared with the deficit 
control group (Dunnett’s multiple comparison test). N.S.: No significant differences were detected in the 
training session. 
4.4 Effects of MT-3014 on CAR test and plasma concentration after oral 
administration 
Next, the time-dependent effect of MT-3014 in the CAR test was evaluated. Oral 
administration of MT-3014 suppressed CAR, in a dose dependent manner (Figure 3A). 
Repeated measures ANOVA revealed the significant effect of MT-3014 (group: 
F3,36 = 20.94, P < 0.01; time: F5,180 = 34.83, P < 0.01, group × time: F15,180 = 10.50, 
P < 0.01). Inhibitory effect was peaked at 1 or 3 hours after oral administration and its 
ID50 values were 0.52 (0.38–0.70) and 0.54 (0.43–0.68) mg/kg. Escape failures were seen 
at higher doses; the largest rate was 34.0 ± 8.6 % in the MT-3014 (1.0 mg/kg) treated 
group at 1 hour after administration (Table 2). 
Plasma MT-3014 concentrations were measured at the same time points using 
satellite animals (Figure 3B). The time-dependent change of plasma MT-3014 
concentration correlated approximately with the time-dependent change of the drug 
efficacy in the CAR test (Figure 3A and 3B). 
A B 
  
Figure 3. Inhibitory effects of MT-3014 on CAR and corresponding plasma MT-
3014 concentration in rats. 
(A): The test sessions were conducted at 1, 3, 5, 7 and 24 hours after the oral administration of MT-3014 
(0.25, 0.5 or 1.0 mg/kg) or vehicle following the pre-test. Data are expressed as mean ± S.E.M. (n = 10). 
*P < 0.05 and **P < 0.01 compared with the vehicle group (repeated measures ANOVA followed by 
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Dunnett’s multiple comparison test). (B): Plasma MT-3014 concentration of satellite animals were 
determined by LC-MS/MS. Data are expressed as mean ± S.D. (n = 3). 
Table 2. Escape failure on each time point in CAR test for MT-3014. 
4.5 Assessment of side effect liability 
The potency of MT-3014 to elicit extrapyramidal side effects and metabolic side 
effects was evaluated. First, the catalepsy test was performed in rats. MT-3014 and 
risperidone, as a reference drug, were evaluated at doses up to approximately 50 times 
their pharmacological doses; the pharmacological dose was defined as each ID50 value in 
the rat CAR test (data of reference drugs are not shown). MT-3014 (1.0–30 mg/kg) caused 
little catalepsy until 7 hours after oral administration (repeated measures ANOVA, group: 
F4,35 = 0.76, P = 0.56, time: F3,105 = 1.20, P = 0.31, group × time: F12,105 = 0.78, P = 0.67), 
whereas risperidone elicited dose-dependent and continuous catalepsy (repeated 
measures ANOVA, group: F4,35 = 12.51, P < 0.01, time: F3,105 = 3.56, P < 0.05, group × 
time: F12,105 = 2.03, P < 0.05) with ED10s values (95% CI) of 10.8 (4.8–24.2) mg/kg 
(Figure 4A and 4B).  
Next, the effect of MT-3014 on increase in plasma prolactin level was evaluated. 
MT-3014 did not increase the plasma prolactin level at doses up to 20 times its 
pharmacological dose (3.0 and 10 mg/kg), whereas risperidone showed significant 
increase at doses around 3 times its pharmacological dose or more (P < 0.01 at 1.0 and 
3.0 mg/kg, Figure 4C). 
Finally, the effect of MT-3014 on body weight change was evaluated. MT-3014 and 
olanzapine, as a reference drug, were evaluated at around the pharmacological effective 
dose because current antipsychotics were reported to produce weight gain effect at around 
their pharmacological dose (Boyda et al., 2010). Repeated administration of MT-3014 
(0.1–1.0 mg/kg) did not affect body weight (repeated measures ANOVA, group: 
F3,20 = 0.42, P = 0.74, time: F20,400 = 94.06, P < 0.01, group × time: F60,400 = 0.53, 
P = 1.00), whereas olanzapine (3.0 mg/kg) showed significantly increase (repeated 
 Escape failures (%) 
 Pre 1 h 3 h 5 h 7 h 24 h 
Vehicle 0 0 0 0 0 0 
0.25 mg/kg 0 0 0 0 0 0 
0.5 mg/kg 0 5.5 ± 3.1 0.5 ± 0.5 0 0 0 
1.0 mg/kg 0 34.0 ± 8.6 28.5 ± 9.5 15.0 ± 7.1 0.5 ± 0.5 0 
Data are expressed as the mean ± S.E.M. (n = 10). 
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measures ANOVA, group: F1,10 = 21.19, P < 0.01, time: F20,200 = 90.36, P < 0.01, group × 
time: F20,200 = 5.85, P < 0.01, Figure 4D). 
A B 
  
C D 
  
Figure 4. Effects of MT-3014 on cataleptogenic activity, plasma prolactin level, and 
body weight change in rats.  
(A): Catalepsy time was measured at 1, 3, 5 and 7 hours after the oral administration of MT-3014 (1.0, 3.0, 
10 or 30 mg/kg), risperidone (5.0, 10, 25 and 50 mg/kg) or vehicle by the bar test (7-cm height, cut-off time 
= 60 sec). Data are expressed as mean ± S.E.M. (n = 8). *P < 0.05 and **P < 0.01 compared with the 
vehicle group (repeated measures ANOVA followed by Dunnett’s multiple comparison test). 
(B): Catalepsy time at each time point was summed and ED10s were calculated from total catalepsy time. 
(C): The plasma prolactin concentration was measured 1 hour after oral administration of MT-3014 (3.0 or 
10 mg/kg), risperidone (1.0 or 3.0 mg/kg) or vehicle using EIA kit. Data are expressed as mean ± S.E.M. 
(n = 5). **P < 0.01 compared with the vehicle group (Dunnett’s multiple comparison test). (D): Body 
weight change by repeated oral administration of MT-3014 (0.1, 0.3 or 1.0 mg/kg), olanzapine (3.0 mg/kg) 
or vehicle. The test compounds were administrated once a day. 
0
5
10
15
20
25
30
35
40
1h 3h 5h 7h
C
at
al
ep
sy
 ti
m
e 
(s
ec
)
Vehicle
MT-3014 1.0 mg/kg
MT-3014 3.0 mg/kg
MT-3014 10 mg/kg
MT-3014 30 mg/kg
Risperidone 5.0 mg/kg
Risperidone 10 mg/kg
Risperidone 25 mg/kg
Risperidone 50 mg/kg
*
**
*
** **
0
20
40
60
80
100
120
Vehicle 1.03.0 10 30 5.0 10 25 50
To
ta
l c
at
al
ep
sy
 ti
m
e 
(s
ec
)
MT-3014 (mg/kg) Risperidone (mg/kg)
ED10s = 10.8 mg/kg
ED10s > 30 mg/kg
0
20
40
60
80
100
120
140
160
Vehicle 3.0 10 1.0 3.0
Pl
as
m
a 
pr
ol
ac
tin
 c
on
ce
nt
ra
tio
n 
(n
g/
m
L)
MT-3014 (mg/kg) Risperidone (mg/kg)
**
**
0
10
20
30
40
50
60
70
0 2 4 6 8 10 12 14 16 18 20
C
ha
ng
es
 in
 b
od
y 
we
ig
ht
 (g
)
Days
Control
MT-3014 0.1 mg/kg
MT-3014 0.3 mg/kg
MT-3014 1.0 mg/kg
Olanzapine 3.0 mg/kg
**
*
* **
**
******
********
****
****
****
37 
 
4.6 Striatal PDE10A occupancy after oral administration of MT-3014 
Using a selective PDE10A PET tracer [11C]IMA107, striatal PDE10A occupancy by 
MT-3014 was assessed. Representative PET images of summed radioactivity from 30 to 
60 min after intravenous injection of [11C]IMA107 was shown in Figure 5A. 
[11C]IMA107 was shown to be selectively distributed at the striatum (baseline) but was 
clearly blocked 1 hour after oral administration of MT-3014 (1 h after). Binding of 
[11C]IMA107 to the striatum recovered 20 hours after administration of MT-3014 (20 h 
after). 
Striatal PDE10A occupancy by several doses of MT-3014 (0.02–6.0 mg/kg) and 
corresponding plasma MT-3014 concentrations are shown in Figure 5B (open triangle 
symbol). Inhibition rates of MT-3014 in the CAR test and corresponding plasma 
MT-3014 concentrations, data of Figure 3, are also plotted in Figure 5B (filled circle 
symbol). Both striatal PDE10A occupancy and inhibition rates in the CAR test relative to 
plasma MT-3014 concentrations resulted in almost overlapping sigmoid curves. The EC50 
values (95% CI) of striatal PDE10A occupancy and inhibition rates in the CAR test were 
58.0 (46.6–69.5) ng/mL and 74.3 (65.5–84.3) ng/mL, respectively.  
A  B
 
Figure 5. Striatal PDE10A occupancy after oral administration of MT-3014 
(A): Representative PET image (30-60 min) after intravenous injection of [11C]IMA107 at baseline, 1 hour 
after or 20 hours after oral administration of MT-3014 (0.45 mg/kg). Images are displayed at the level of 
the striatum in coronal. (B): Striatal PDE10A occupancy, inhibition ratio in CAR test and corresponding 
plasma MT-3014 concentration were plotted.  
 
Baseline 1 h after 20 h after 
Striatum
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5 Discussion 
Here we demonstrated the antipsychotic-like effect of MT-3014 (Koizumi et al., 
2019) in rats. MT-3014 showed a potent inhibitory effect against PDE10A with high 
selectivity over other PDE families and other primary off-targets. Oral administration of 
MT-3014 increased striatal cAMP, cGMP and CREB phosphorylation at doses of 
1.0 mg/kg or more, indicating MT-3014 has good biological activity. For assessment of 
antipsychotic-like effects, MK-801-induced rat models have been widely used (Cadinu et 
al., 2018; Gobira et al., 2013). MT-3014 showed an inhibitory effect on MK-801-induced 
hyperactivity with an ED50 value of 0.30 mg/kg (p.o.), however also decreasing 
spontaneous locomotor activity with an ED50 value of 0.48 mg/kg (p.o.). In the PPI and 
NORT, MT-3014 improved MK-801-induced PPI deficits and cognitive deficit at doses 
under 1.0 mg/kg (p.o.). In the CAR test (Wadenberg, 2010), MT-3014 showed inhibitory 
effect in a dose- and time-dependent manner according to the plasma MT-3014 level 
change. The peak of the effect of MT-3014 was at 1-3 hours after oral administration with 
ID50 values of 0.52 (1 h) and 0.54 (3 h) mg/kg (p.o.). After 24 h of administration, 
MT-3014 exposure almost disappeared, and its inhibitory effect also disappeared in the 
CAR test. These data suggest that MT-3014 has antipsychotic-like effects in rats. 
In the treatment for schizophrenia with current antipsychotics, several adverse 
effects including EPS and metabolic side effects remain problematic (De Hert et al., 2016; 
Krebs et al., 2006; Serretti et al., 2004; Tschoner et al., 2007). To assess the potency of 
MT-3014 to elicit these adverse effects, we evaluated MT-3014 in three typical tests in 
rats. MT-3014 did not elicit catalepsy or increase plasma prolactin levels at excess 
pharmacological doses, whereas risperidone elicited strong and contentious catalepsy or 
increased plasma prolactin levels at less than 10- or 2- fold the pharmacological dose. 
MT-3014 did not affect body weight at around the pharmacological dose, whereas 
olanzapine did. These results suggest that MT-3014 is very unlikely to cause side effects 
observed in current antipsychotics. 
Translational research is very important for conducting safe and effective clinical 
trials. In this study, the relationship of MT-3014 between pharmacological effect and 
striatal PDE10A occupancy in rats was investigated using a selective PDE10A PET tracer 
[11C]IMA107 (McCluskey et al., 2019; Plisson et al., 2014). Both the striatal MT-3014 
PDE10A occupancy rates and effects of MT-3014 in CAR showed plasma MT-3014 
concentration-dependent increases respectively, the two response curves almost 
overlapping, with nearly equivalent EC50 values. It is likely that MT-3014 binds to 
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PDE10A in the striatum and it is possible to predict receptor occupancy from plasma 
MT-3014 concentrations.  
Although the clinical trials of MP-10 and TAK-063 for treatment of schizophrenia 
could not achieve proof of the therapeutic effect of PDE10A inhibitors (NCT01175135, 
DeMartinis et al., 2019; Macek et al., 2019), human PET studies related to these clinical 
trials demonstrated that the doses used were shown to occupy less than 50% of brain 
PDE10A (Delnomdedieu et al., 2017; Takano et al., 2016). MP-10 showed poor 
tolerability, making it difficult to increase dosing (Delnomdedieu et al., 2017). However, 
a couple of other compounds were tolerated at higher doses and showed better occupancy 
of brain PDE10A (Takano et al., 2016; Yu, 2014). One of the approaches to show better 
efficacy of PDE10A inhibitors for treatment of schizophrenia without adverse effects 
might be to find a dosing resume that can keep an adequate brain PDE10A occupancy for 
a longer duration. 
In this study, striatal PDE10A occupancy was increased in the plasma concentration-
dependent manner after oral administration of MT-3014 in the pharmacological dose 
range in rats. This result suggested that the striatal PDE10A occupancy could be estimated 
by plasma concentration and that brain PDE10A occupancy monitoring could be possible 
by a less-invasive approach: blood concentration monitoring. Of course, since there may 
be species difference between rats and humans, it is important to clarify the relationship 
between the plasma concentration of MT -3014 and brain PDE10A occupancy by a Phase 
1 clinical PET study, but the plasma concentration of MT-3014 could be a good predictor 
of brain PDE10A occupancy in subsequent large-scale clinical studies. 
Finally, the effect of MT-3014 on negative symptoms of schizophrenia is yet to be 
determined. TAK-063 suggested the possibility of the effectiveness for negative 
symptoms (Macek et al., 2019), and clinical trials of Lu AF11167 for the treatment of 
negative symptoms of schizophrenia are now undergoing (NCT03793712 and 
NCT03929497). Non-clinical investigations of MT-3014 looking into the relationship of 
effects on negative symptoms of schizophrenia, brain occupancy and plasma 
concentration should support the design of adequate future clinical trial plans. 
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6 Conclusion 
In this study, we demonstrated that a novel PDE10A inhibitor MT-3014 showed 
antipsychotic-like and pro-cognitive effects in rat models of schizophrenia. It is likely 
that MT-3014 would be a novel antipsychotic drug. 
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IV. CONCLUSION 
In this study, the potency of novel PDE10A inhibitors for the treatment of 
schizophrenia was investigated in rodent models. In chapter 1, T-251 suppressed CAR 
and MK-801-induced hyperactivity, PPI deficits and cognitive deficits, suggesting T-251 
effects not only for positive symptoms and cognitive impairment. In addition, T-251 
showed less side effects that are problems in currently-used typical antipsychotics (i.e. 
EPS and hyperprolactinemia). In chapter 2, MT-3014 showed a similar pharmacological 
effect and less side effect liability including metabolic side effect which is new issue in 
atypical antipsychotics. These results supported the nonclinical data of previously 
reported PDE10A inhibitors and suggested that PDE10A inhibitors could be novel 
therapeutic agents for schizophrenia that meets unmet needs. 
On the other hand, several clinical trials for PDE10A inhibitors in patients with 
schizophrenia have not been successful to date. In the first POC study, MP-10 did not 
exert its therapeutic effect, and dose increase was abandoned due to the adverse effects. 
TAK-063 also did not achieve the primary endpoint at a dose expected to exert its efficacy 
based on the nonclinical data. However, TAK-063 was also reported to be tolerant at 
higher doses than those used in the POC study. Additional nonclinical research revealed 
that TAK-063 and MP-10 have differences in the activation balance between direct 
pathway and indirect pathway. These data suggest that different chemotypes of PDE10A 
inhibitors might different actions and be worth investigating in another POC study. 
Clinical PET studies of these two compounds showed that brain PDE10A occupancy 
was less than 50% by both compounds at the doses used. There is a sufficient possibility 
that PDE10A inhibitors exert the efficacy without the adverse effect at a higher occupancy. 
Rat CAR test is widely used to estimate the clinical dose, but that is based on the 
correlation using current antipsychotics, D2 inhibitors. Given the information above, the 
clinical dose of PDE10A inhibitors may have to be estimated from the dose that shows 
higher inhibition in rat CAR test. 
Such translational research is a key to successful clinical trials. Rat PET study in this 
study chapter 2 revealed that plasma concentration of MT-3014 was correlated with the 
brain occupancy and with inhibitory effect on CAR test, and the dose ranges were 
overlapped. This suggests that the brain occupancy targeted based on rat CAR data could 
be controlled with plasma concentration monitoring. This is useful information to conduct 
successful clinical trial with strategies described above. 
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A POC study of another PDE10A inhibitor Lu AF11167 for negative symptoms is 
currently ongoing. Both T-251 and MT-3014 did not evaluated for negative symptoms in 
this study, but it is expected that they would also effect on negative symptoms based on 
nonclinical researches of other PDE10A inhibitors. In previous POC studies, MP-10 and 
TAK-063 failed to achieve the comprehensive assessment for schizophrenia (PANSS 
total score). However, since TAK-063 showed efficacy in several evaluation items for 
negative symptoms, stratification of patients might be one of the ways to be more 
successful. 
In conclusion, the potential of PDE10A inhibitors for the treatment of schizophrenia 
is promising at a nonclinical level. PDE10A inhibitors might require a different approach 
to success to achieve POC than previous studies, but be expected to be a new treatment 
that addresses unmet needs. 
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